Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Disease: Cardiovascular and Circulatory System


[Search within category]

A Potent and Selective FXIa Inhibitor as a Next-generation Antithrombotic Drug

UCSF partnered with Pfizer’s Centers for Therapeutic Innovation (CTI) to identify an IND-ready antibody directed towards the treatment of thrombotic disease. The asset is a fully human antibody targeting the coagulation cascade serine protease FXIa for currently underserved thrombotic disease indications. A potent reversal agent has also been developed.

Diagnosis and Treatment of Arteriovenous Malformations

UCLA researchers in the Departments of Molecular, Cell, and Development Biology & Surgery have identified Angiopoietin 2 (Ang-2) as a marker and potentially a strong contributing factor to the clinical presentation of pulmonary arteriovenous malformations.

AGPAT5 as a Molecular Mediator of Insulin Resistance

UCLA researchers in the Departments of Medicine and Cardiology have identified a novel gene and pathway in the regulation of insulin sensitivity and discovered an inhibitor of this gene useful for treating AGPAT5-related diseases.

Bidirectional IVC Filter

Researchers at UCLA from the Department of Radiology have developed an improved IVC filter with better filtering performance that is easily retrievable.

Half-Virtual-Half-Physical Microactuator

Researchers at the University of California, Davis have developed a half-virtual-half-physical microactuator that utilizes a combination of computational models and microelectromechanical systems for use in medical devices and mechanical systems.

A Gene Therapy Strategy To Restore Electrical And Cardiac Function In Arrhythmogenic Right Ventricular Cardiomyopathy

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a predominantly genetic-based heart disease characterized by right but also recently left ventricular dysfunction, fibrofatty replacement of the myocardium leading to fatal/severe ventricular arrhythmias leading to sudden cardiac death in young people and athletes. ARVC is responsible for 10% of sudden cardiac deaths in people ≥65 years of age and 24% in people ≤30 years of age. ARVC is thought to be a rare disease as it occurs in 1 in 1000-5000 people, although the prevalence may be higher as some patients are undiagnosed or misdiagnosed due to poor diagnostic markers. Growing evidence also reveals earlier onset since pediatric populations ranging from infants to children in their teens are also particularly vulnerable to ARVC, highlighting the critical need to identify and treat patients at an earlier stage of the disease.At present there are no effective treatments for ARVC nor has there been any randomized clinical trials conducted to examine treatment modalities, screening regimens, or medications specific for ARVC. As a result, treatment strategies for ARVC patients are directed at symptomatic relief of electrophysiological defects, based on clinical expertise, results of retrospective registry-based studies, and the results of studies on model systems. The current standard of care is the use of anti-arrhythmic drugs (sotalol, amniodarone and beta-blockers) that transition into more invasive actions, which include implantable cardioverter defibrillators and cardiac catheter ablation, if the patient becomes unresponsive or intolerant to anti-arrhythmic therapies. However, current therapeutic modalities have limited effectiveness in managing the disease, 40% of ARVC patients (a young heart disease) die within 10-11 years after initial diagnosis, highlighting the need for development of more effective therapies for patients with ARVC.

Mobile Phone Based Fluorescence Multi-Well Plate Reader

UCLA researchers have developed a novel mobile phone-based fluorescence multi-well plate reader.

Vessel Cross-Sectional Area Measurements Using CT Angiography

A new approach to visualizing small and stenotic vasculature not readily visible with modern day diagnostic computed tomography angiography.

Single Ended Draw Lines For Medical Device Application

Minimizing the movement of deployed transcatheter heart valves and stents during detachment using single ended draw lines.

Ultrasound-Guided Delivery System For Accurate Positioning - Repositioning Of Transcatheter Heart Valves

Utilizing intravascular ultrasound for accurate placement of transcatheter heart valves to improve surgical outcomes.

Novel Nanoliposomal Nitroglycerin Formulation for Cardiovascular Therapies

    To address this major limitation, investigators at UCR have developed a nanoliposomal formulation of NTG, which achieves a 70-fold increase in the anti-inflammatory effect of NTG when compared to NTG. This increase in potency allows lower doses to be effective, which could mitigate the common issues seen with high clinical doses of NTG viz. loss of NTG sensitivity and endothelial toxicity. Fig. 1 Adhesion of U937 monocytes to NO-deficient (L-NIO-treated) ECs is significantly blocked by treating ECs with 5 ug/ml nanoliposomal nitroglycerin (NTG-NL). L-NIO is a selective eNOS inhibitor.  Remarkably, this anti-inflammatory dose of NTG in nanoliposomes is 70-fold lower than the dose of free NTG (5uM) required to achieve a similar effect

Automated Reconstruction Of The Cardiac Chambers From MRI

This is a fast, fully automated method to accurately model a patient’s left heart ventricle via machine learning algorithms.

A Novel Method and Apparatus to Access the Left Heart for Cardiac Interventions

UCLA researchers in the Division of Cardiology at the Geffen School of Medicine have developed novel devices and methods for allowing entirely intravascular access to the left ventricle, thereby precluding access via the apex of the heart percutaneously or by surgery.

Injectable Novel Therapeutic for Post-Myocardial Infarction Repair

Cardiovascular disease manifested as a myocardial infarction (MI) usually results in the irreversible death of heart muscle cells. While medical treatments can mitigate some symptoms, they often fail to prevent heart failure after a MI. The current standard of care for MI relies on surgical intervention via a coronary artery bypass. An alternative therapeutic approach has been taken in the last few years with the introduction of biomaterials designed to promote neovascularization after an MI and help prevent negative left ventricle remodeling by increasing infarct wall thickness and decreasing volume, fibrosis, and infarct size. 

Novel Anti-Bacterial, Anti-Fungal Nanopillared Surface

Medical devices are susceptible to contamination by harmful microbes, such as bacteria and fungi, which form biofilms on device surfaces. These biofilms are often resistant to antibiotics and other current treatments, resulting in over 2 million people per year suffering from diseases related to these contaminating microbes. Death rates for many of these diseases are high, often exceeding 50%. Researchers at UCI have developed a novel anti-bacterial and anti-fungal biocomposite that incorporates a nanopillared surface structure that can be applied as a coating to medical devices.

Monoclonal Antibodies to Oxidation-Specific Epitopes

The leading cause of death worldwide is cardiovascular disease, primarily atherosclerosis, which is recognized as a chronic inflammatory disease. This inflammation occurs within the arterial wall and is initiated in part by the oxidation of low-density lipoproteins (OxLDL), which in turn can stimulate both innate and adaptive immune responses. In cellular process of the oxidation of LDL, a number of oxidation-specific neo-epitopes are formed. One such product is malondialdehyde (MDA), produced by degradation by reactive oxygen species, which can further react with acetaldehyde and endogenous proteins, forming malondialdehyde-acetaldehyde (MAA) adducts. These MAA adducts are immunogenic and have proinflammatory properties. Furthermore, circulating levels of antibodies against MAA adducts have been shown to correlate with atherosclerotic disease and be involved in other diseases, such as liver and neurological diseases.

Sieve Container For Contactless Media Exchange For Cell Growth

Media that contains nutrients and growth factors is necessary to grow all types of cells, a process that is widely used in many fields of research. Such media should be routinely changed either to different media or a fresh batch of the same media. This change currently involves either using a pipette to transfer cells from their current dish of media to a new dish, or aspirating the media out of the dish and replacing it with new media. Both methods have inherent risks to stressing and damaging the cells. Researchers at UCI have developed a unique dish for growing cells that allows for safer aspiration of the old media, which reduces stress and damage to the cells.

Improved Free Fractional Flow Reserve (FFR) Measurement for Coronary Heart Disease Diagnosis

A free fractional flow reserve (FFR) measurement is a powerful tool for physicians to diagnose coronary heart disease. Adenosine or a related vasodilator agent is needed to prepare the patient for the procedure. Unfortunately, in addition to the cost, adenosine can cause debilitating side effects. The UCI inventors have developed a safer, less-expensive method of performing FFR.

Breast Lesion Characterization Using Contrast Mammography

Breast cancer is the most common cancer in women in the U.S. As with any cancer, early detection and treatment is critical in minimizing the severity of the tumor and risk of death. Researchers at UCI School of Medicine have developed a novel contrast-enhanced mammography technique capable of distinguishing between benign and malignant lesions in breast tissue.

Estimation Of Contrast Concentration From Angiograms In Presence Of Vessel Overlap

UCLA researchers have developed an image processing technique for quantitative measurement of brain hemodynamics using x-ray digital subtraction angiography (DSA) images. 

Non-Invasive Method For Determination Of Tissue Electrical Conductivity

UCLA researchers in the UCLA Semel Institutes of Neuroscience and Behavior have developed a non-invasive method to locate and estimate electrical currents in organs such as the brain and heart.

Small Molecule Inhibitors of Cardiovascular and Renal Ectopic Calcification

UCLA researchers in the Department of Medicine have discovered that administration of small molecule inhibitors of ENPP1 or functional antagonists of PPi can substantially attenuate ectopic calcification. This suggests that ENPP1 and PPi can be potential pharmacological targets when developing therapeutics for pathological ectopic calcification.

Microchambers With Solid-State Phosphorescent Sensor For Measuring Single Mitochondrial Respiration

The invention is a miniaturized device that assays the respiration of a single mitochondrion. Through a novel approach for measuring oxygen consumption rate, the device provides information on cell and tissue mitochondrial functional. This data is relevant for understanding human conditions associated with mitochondrial dysfunction, such as Alzheimer’s Disease and cancer.

A Novel Method to Generate Specific and Permanent Macromolecular Covalent Inhibitors

UCSF researchers have invented a novel method to generate covalent macromolecular inhibitors. This strategy allows a peptide inhibitor to bind to its target protein specifically and irreversibly through proximity-enabled bioreactivity.

Hybridoma Producing Antibodies To C1qRp

Individuals with genetic immunodeficiency, as well as patients with HIV, cancer, and those undergoing chemotherapy or high risk surgery, are at increased risk for infection. C1q, an important component of the immune system, is known to enhance phagocytosis (cell ingestion of harmful bacteria or other materials). Scientists at UCI have developed antibodies to the receptor for C1q, C1qRp, to be used as a target for prophylactic treatments in populations at high risk of infection.

  • Go to Page: